March 2012
You are browsing the archive for March 2012.
Orphan drug policies make drug research for rare diseases viable in the U.S. but not in Canada
Business in Vancouver, March 20, 2012
From a sheer market perspective, Allon Therapeutics’ decision to focus on a rare a neurological disorder called progressive supranuclear palsy (PSP) doesn’t add up. After all, only 20,000 North Americans have the disease, compared with 4.4 million Alzheimer’s victims….
